Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Starting soon Phase 1

A Clinical Study of AHB-121 in Healthy Participants and Chronic Hepatitis B (CHB) Participants

NCT07884864 · tracked via the Priya Life Science China tracker
Phase
Phase 1
Started
2026-10-28
Last updated
2026-10-21

Condition(s) studied

Chronic Hepatitis B Virus

Investigational drug(s) / intervention(s)

AHB-121Placebo

AHB-121: AHB-121 will be used per week

Placebo: Placebo will be used per week

Study summary

This is a clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AHB-121 injection in healthy and chronic hepatitis B participants.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Sign the informed consent form and be able to complete the research as required. * Age and weight meet the requirements. * During the screening, the results of physical examination, vital signs, laboratory tests, electrocardiogram, etc. are normal or have no clinical significance(healthy individuals). * Take effective contraceptive measures as required. * During the screening, HBsAg, HBV DNA, ALT, and HBeAg meet certain indicators (CHB participants). Exclusion Criteria: * Have a serious systemic disease or a history of malignant tumor. * Have other liver diseases besides chronic HBV infection, or have liver dysfunction, significant liver fibrosis/ cirrhosis, history of liver cell carcinoma or suspected cases. * Have autoimmune diseases or diseases with a risk of immune activation. * Have a questionable allergy to the test drugs and their components, or have an allergic constitution. * Participate in other clinical trials or receive investigational drug treatment within the specified time before screening, and have received related drug * Have received solid organ transplantation or hematopoietic stem cell transplantation before screening. * Have acute infection, major trauma or major surgery with clinical significance that has not fully recovered within the specified time before screening, or have a surgical plan during the study. * Have abnormal laboratory tests, vital signs or electrocardiogram results during screening and have clinical significance as judged by the researcher. * Have positive screening for related infectious diseases. * Have a history of drug abuse or alcoholism; or have a large amount of smoking before screening and cannot stop during the study. * Have consumed caffeine, xanthine-containing foods or beverages, or engaged in intense exercise within the specified time before administration, or have been unable to stop during the study. * Have positive urine drug screening or alcohol breath test during screening; have donated blood or lost a large amount of blood before screening, received blood transfusion, or have a blood donation plan during the study. * Have a positive pregnancy test during screening. * Abnormal skin at the injection site. * Have a history of fainting or hemisomnia, difficulty in blood collection, or inability to tolerate venipuncture blood collection. * The researcher considers that there are other factors that make one unsuitable to participate in this trial.

Primary outcome measure(s)

  • Safety indicators — Up to 18weeks
    Incidence and severity of TEAE/SAE; changes in laboratory tests, ECG, physical examination, and vital signs compared to baseline

Trial sites (1)

FacilityCityRegionStatus
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Shanghai Shanghai Municipality
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07884864 on ClinicalTrials.gov ↗ ← All trials in China